From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
KLTWQELYQLKYKGI (QK) is a VEGF mimicking peptide, binds to the VEGFreceptors and competes with VEGF. KLTWQELYQLKYKGI is active in gastric ulcer healing in rodents when administered either orally or systemically. KLTWQELYQLKYKGI shows the ability to induce capillary formation and organization in vitro .
Lavendustin A (RG-14355) is a potent, selective and ATP-competitive inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, with an IC50 of 11 nM. Lavendustin A does not inhibit protein kinase A or C. Lavendustin A can suppress VEGF-induced angiogenesis .
HC-5404-Fu is a PERK inhibitor with an antitumor activity. HC-5404-Fu inhibits endoplasmic reticulum stress response signalling. HC-5404-Fu sensitizes renal cell carcinoma cells to vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitors (TKIs). HC-5404-Fu is promising for research of renal cell carcinoma, gastric cancer, metastatic breast cancer, small cell lung cancer, and other solid tumors .
Gersizangitide (AXT107) is an anti-angiogenic peptide consisting of 20 amino acids, derived from collagen IV. Gersizangitide is an inhibitor of VEGF-A and VEGF-C and an activator of Tie2. Gersizangitide can block VEGFreceptor signaling, inhibit vascular leakage, neovascularization and inflammation. Gersizangitide can be used in the research of diseases related to ocular neovascularization and angiogenesis .
Roxatidine is an active metabolite of Roxatidine acetate hydrochloride, is an orally active histamine H2-receptor antagonist. Roxatidine, an anti-ulcer agent, suppresses histamine release (thus inhibiting proton secretion) and inhibits the production of VEGF-1, an important marker of inflammation and angiogenesis. Anti-allergic inflammatory effect. Roxatidine is promising for research of gastric and duodenal ulcers .
Lavendustin A (Standard) is the analytical standard of Lavendustin A. This product is intended for research and analytical applications. Lavendustin A (RG-14355) is a potent, selective and ATP-competitive inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, with an IC50 of 11 nM. Lavendustin A does not inhibit protein kinase A or C. Lavendustin A can suppress VEGF-induced angiogenesis[1][2].
Human KDR mRNA encodes the human kinase insert domain receptor (KDR) protein, a receptor of vascular endothelial growth factor (VEGF). KDR functions as the main mediator of VEGF-induced endothelial proliferation, survival, migration, tubular morphogenesis and sprouting.
VGB4 is a VEGF-A and VEGF-B antagonist peptide that duplicates two binding domains of VEGF-B (loop 1 and loop3) and are linked together by the receptor-binding domain of VEGF-A (loop3). VGB4 has significant anti-angiogenic and anti-tumor activities and can regulate tumor growth and metastasis through multiple mechanisms. VGB4 could be used in anti-tumor research .
Roxatidine (Standard) is the analytical standard of Roxatidine. This product is intended for research and analytical applications. Roxatidine is an active metabolite of Roxatidine acetate hydrochloride, is a histamine H2-receptor antagonist. Roxatidine, an anti-ulcer agent, suppresses histamine release (thus inhibiting proton secretion) and inhibits the production of VEGF-1, an important marker of inflammation and angiogenesis. Anti-allergic inflammatory effect .
Azaspirene ((-)-Azaspirene) is an angiogenesis and Raf-1 activation inhibitor isolated from the fungus Neosartorya sp. Azaspirene inhibits vascular endothelial growth factor (VEGF)-induced human umbilical vein endothelial cell (HUVEC) migration and Raf-1 activation, but has no effect on the activation of kinase insert domain-containing receptor/fetal liver kinase 1 (VEGFreceptor 2) .
Mizolastine dihydrochloride is an orally active, high affinity and specific peripheral histamine H1 receptor antagonist (second generation antihistamine). Mizolastine dihydrochloride effectively inhibits mRNA expression of VEGF165, VEGF120, TNF-α and KC. Mizolastine dihydrochloride can be used in studies of allergic rhinitis and chronic idiopathic urticarial .
Mizolastine is an orally active, high affinity and specific peripheral histamine H1 receptor antagonist (second generation antihistamine). Mizolastine effectively inhibits mRNA expression of VEGF165, VEGF120, TNF-α and KC. Mizolastine can be used in studies of allergic rhinitis and chronic idiopathic urticarial .
Dovitinib (dilactic acid) is an orally active inhibitor of VEGF kinase. Dovitinib (dilactic acid) inhibits receptor tyrosine kinases (RTKs) involved in solid and hematologic cancers and tumor angiogenesis .
Mizolastine (Standard) is the analytical standard of Mizolastine. This product is intended for research and analytical applications. Mizolastine is an orally active, high affinity and specific peripheral histamine H1 receptor antagonist (second generation antihistamine). Mizolastine effectively inhibits mRNA expression of VEGF165, VEGF120, TNF-α and KC. Mizolastine can be used in studies of allergic rhinitis and chronic idiopathic urticarial .
Vanucizumab is a first-in-class, bispecific IgG1-like monoclonal antibody that simultaneously blocks VEGF-A and angiopoietin-2 (Ang-2) from interacting with their receptors. Vanucizumab has antiangiogenic and anticancer effects .
Carebastine is the active metabolite of Ebastine. Carebastine is a histamine H1 receptor antagonist. Carebastine inhibits VEGF-induced HUVEC and HPAEC proliferation, migration and angiogenesis in a dose-dependent manner . Carebastine suppresses the expression of macrophage migration inhibitory factor .
EG00229 is a neuropilin 1 (NRP1) receptor antagonist. EG00229 selectively inhibits VEGF-A binding to NRP1 b1 domain with an IC50 of 3 μM, but has no effect on VEGFA binding to VEGFR-1 and VEGFR-2 .
Inlecitug is a chimeric monoclonal antibody targeting human KDR (kinase insert domain receptor). Inlecitug specifically binds to KDR, blocking the binding of vascular endothelial growth factor (VEGF) to KDR and inhibiting angiogenesis, thus exerting antitumor activity. Inlecitug is promising for research of cancers .
Tirofiban (L700462) is a selective and reversible platelet integrinreceptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .
Tirofiban (L700462) hydrochloride is a selective and reversible platelet integrinreceptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban hydrochloride induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban hydrochloride can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .
Tirofiban (L700462) hydrochloride monohydrate is a selective and reversible platelet integrinreceptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban hydrochloride monohydrate induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban hydrochloride monohydrate can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .
Carebastine-d5 is the deuterium labeled Carebastine. Carebastine is the active metabolite of Ebastine. Carebastine is a histamine H1 receptor antagonist. Carebastine inhibits VEGF-induced HUVEC and HPAEC proliferation, migration and angiogenesis in a dose-dependent manner . Carebastine suppresses the expression of macrophage migration inhibitory factor .
Carebastine-d5 Methyl Ester is the deuterium labeled Carebastine. Carebastine is the active metabolite of Ebastine. Carebastine is a histamine H1 receptor antagonist. Carebastine inhibits VEGF-induced HUVEC and HPAEC proliferation, migration and angiogenesis in a dose-dependent manner . Carebastine suppresses the expression of macrophage migration inhibitory factor .
AKB-6899, a prolyl hydroxylase domain 3 (PHD3) inhibitor, is a selective HIF-2α stabilizer. AKB-6899 also increases soluble form of the VEGFreceptor (sVEGFR-1) production from GM-CSF-treated macrophages, and has antitumor and antiangiogenic effects .
Capeserod (SL65.0155 free base) is an agonist for serotonin receptor (5-HT receptor), with a Ki of 0.6 nM for 5-HT4receptor. Capeserod enhances expression of phopshorilated cAMP-response element binding protein (p-CREB), vascular endothelium growth factor (VEGF), brain-derived neurotrophic factor (BDNF) and B cell lymphoma-2 (Bcl-2) proteins in hippocampus, and exhibits antidepressant-like efficacy in Wistar rats models .
hVEGF-IN-2 (compound 19) is a selective VEGF (Flk-1) receptor tyrosine kinases (RTK) inhibitor with an IC50 value of 2.5 μM. hVEGF-IN-2 inhibits PDGF RTK activity with an IC50 value of 33.1 μM. hVEGF-IN-2 can be used for the development of RTK-specific agents .
Quininib is a cysteinyl leukotriene 1 and 2 receptor antagonist with IC50s of 1.2 and 52 μM for CysLT1R and CysLT2R, respectively. Quininib is a potent inhibitor of developmental angiogenesis in the zebrafish eye. Quininib can be used for the research of ocular neovascular pathologies and may complement current anti-VEGF biological agents .
AhR modulator-1 (compound 6-MCDF) is a selective and orally active aryl hydrocarbon receptor (AhR) modulator. AhR modulator-1 inhibits metastasis, in part, by inhibiting prostatic VEGF production prior to tumor formation. AhR modulator-1 also possess anti-estrogenic properties in rat uterus .
Tirofiban (hydrochloride monohydrate) (Standard) is the analytical standard of Tirofiban (hydrochloride monohydrate). This product is intended for research and analytical applications. Tirofiban (L700462) hydrochloride monohydrate is a selective and reversible platelet integrinreceptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban hydrochloride monohydrate induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban hydrochloride monohydrate can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .
Tirofiban (Standard) is the analytical standard of Tirofiban. This product is intended for research and analytical applications. Tirofiban (L700462) is a selective and reversible platelet integrinreceptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .
AFG210 is a potent multi-target kinase inhibitor that primarily inhibits Abl kinase (IC50=330 nM), and also has inhibitory effects on other kinases such as B-Raf, C-Raf, FGFR-1, RET and VEGFreceptors. AFG210 can be used to study chronic myeloid leukemia and other diseases with abnormal activation of Abl kinase .
Asterric acid is an antibiotic fungal metabolite that completely inhibits the binding of the potent vasoconstrictor endothelin (ET)-1 to the ETA receptor in A10 cells at 0.1 μM.1 Asterric acid derivatives have also been shown to inhibit VEGF-induced tube formation of human umbilical vein endothelial cells at 3-10 μM, which suggests its usefulness as an antiangiogenic agent.
DSPE-PEG3400-K237 is a PEG compound which composed of DSPE and a KDR targeting peptide (K237). K237 can functionally disrupt the interaction between VEGF and the KDR receptor and cause potent biological effects that include the inhibition of angiogenesis and tumor growth. DSPE-PEG3400-K237 can be used for drug delivery .
DSPE-PEG5000-K237 is a PEG compound which composed of DSPE and a KDR targeting peptide (K237). K237 can functionally disrupt the interaction between VEGF and the KDR receptor and cause potent biological effects that include the inhibition of angiogenesis and tumor growth. DSPE-PEG5000-K237 can be used for drug delivery .
DSPE-PEG2000-K237 is a PEG compound which composed of DSPE and a KDR targeting peptide (K237). K237 can functionally disrupt the interaction between VEGF and the KDR receptor and cause potent biological effects that include the inhibition of angiogenesis and tumor growth. DSPE-PEG2000-K237 can be used for drug delivery .
DSPE-PEG1000-K237 is a PEG compound which composed of DSPE and a KDR targeting peptide (K237). K237 can functionally disrupt the interaction between VEGF and the KDR receptor and cause potent biological effects that include the inhibition of angiogenesis and tumor growth. DSPE-PEG1000-K237 can be used for drug delivery .
SU16f is a potent and selective PDGFRβ inhibitor with IC50s of 10 nM, 140 nM, 2.29 μM for PDGFRβ, VEGF-R2, FGF-R1, respectively . Neutralization of PDGFRβ receptor by SU16f blocks the promoting role of GC-MSCs (gastric cancer-derived mesenchymal stem cells) conditioned medium in gastric cancer cell proliferation and migration .
MG-262 (Z-Leu-Leu-LeuB(OH)2; ZL3B) is a reversible proteasome inhibitor. MG-262 down-regulates VEGFreceptor Flt-1. MG-262 inhibits cell growth and induces apoptosis in malignant cells. MG-262 induces reactive oxygen species (ROS). MG-262 can be used for anti-cancer study .
Nastorazepide (Z-360) is an orally active 1,5-benzodiazepine derivative and gastrin/CCK-2receptor antagonist. Nastorazepide inhibits the specific binding of [ 3H]CCK-8 to the human CCK-2 receptor with a Ki value of 0.47 nM. Nastorazepide inhibits IL-1β, ephrin B1, VEGF, and HIF-1alpha, reduces Akt and NR2B phosphorylation. Nastorazepide has antitumor activity against pancreatic cancer. Nastorazepide inhibits colorectal cancer liver metastasis and relieves pain .
YLL545 is a type of vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor. YLL545 can inhibit VEGF-induced phosphorylation of VEGFR2 and the activation of downstream signaling factors (like phosphorylated STAT3 and phosphorylated ERK1/2) in human umbilical vein endothelial cells (HUVEC). YLL545 can suppress the proliferation, migration, invasion, and angiogenesis of HUVEC. YLL545 can induce apoptosis in breast cancer mice and inhibit tumor growth .
JK-P3 is a potent and pan VEGFR2 inhibitor, with IC50s of 7.83 μM, 27 μM and 5.18 μM for VEGFR2, FGFR1 and FGFR3, respectively. JK-P3 can inhibit VEGF-A-stimulated VEGFR2 activation and intracellular signalling, also inhibits endothelial monolayer wound closure and angiogenesis, as well as fibroblast growth factor receptor kinase activity in vitro. JK-P3 has anti-angiogenic activity .
YF-452 is a potent inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2). YF-452 remarkably inhibits the migration, invasion and tube-like structure formation of human umbilical vein endothelial cells (HUVECs) with little toxicity. YF-452 inhibits VEGF-induced phosphorylation of VEGFR2 kinase and the downstream protein kinases including extracellular signal regulated kinase (ERK), focal adhesion kinase (FAK) and Src. YF-452 is a potential antiangiogenic agent candidate for cancer research .
Nastorazepide (Z-360) hemicalcium is an orally active 1,5-benzodiazepine derivative and gastrin/CCK-2receptor antagonist. Nastorazepide hemicalcium inhibits the specific binding of [ 3H]CCK-8 to the human CCK-2 receptor with a Ki value of 0.47 nM. Nastorazepide hemicalcium inhibits IL-1β, ephrin B1, VEGF, and HIF-1alpha, reduces Akt and NR2B phosphorylation. Nastorazepide hemicalcium has antitumor activity against pancreatic cancer. Nastorazepide hemicalcium inhibits colorectal cancer liver metastasis and relieves pain .
Nastorazepide (Standard) is the analytical standard of Nastorazepide. This product is intended for research and analytical applications. Nastorazepide (Z-360) is an orally active 1,5-benzodiazepine derivative and gastrin/CCK-2 receptor antagonist. Nastorazepide inhibits the specific binding of [3H]CCK-8 to the human CCK-2 receptor with a Ki value of 0.47 nM. Nastorazepide inhibits IL-1β, ephrin B1, VEGF, and HIF-1alpha, reduces Akt and NR2B phosphorylation. Nastorazepide has antitumor activity against pancreatic cancer. Nastorazepide inhibits colorectal cancer liver metastasis and relieves pain .
(rac)-ZK-304709 is an isoform of ZK-304709 and is an orally active multi-targeted tumor growth inhibitor that inhibits multiple cell cycle-dependent kinases (CDKs), vascular endothelial growth factor receptor kinases (VEGF-RTKs), and platelet-derived growth factor receptor kinase β (PDGF-RTKβ). (rac)-ZK-304709 can dose-dependently inhibit the proliferation and colony formation of neuroendocrine tumor (NET) cells. (rac)-ZK-304709 directly acts on NET cells by inducing G2 cell cycle arrest and apoptosis, while reducing the expression of MCL1, survivin, and HIF1α. (rac)-ZK-304709 effectively controls tumor growth by inducing apoptosis and inhibiting tumor-induced angiogenesis, and may become a potential agent for inhibiting NET .
Boc-Phe-Leu-Phe-Leu-Phe (Boc-FLFLF) is a N-formyl peptide receptors (FPR) inhibitor. Boc-Phe-Leu-Phe-Leu-Phe abolishes the FMLP-induced release of peptide leukotrienes. Boc-Phe-Leu-Phe-Leu-Phe inhibits the sprouting of human umbilical vein endothelial cell (HUVEC) spheroids mediated by proliferative diabetic retinopathy (PDR) vitreous and vascular endothelial growth factor (VEGF) respectively in a three-dimensional fibrin gel. Boc-Phe-Leu-Phe-Leu-Phe inhibits the anti-inflammatory and antifibrotic effects of Ac2-26 (HY-P1098). Boc-Phe-Leu-Phe-Leu-Phe can be used for the study of immunology .
DSPE-PEG3400-K237 is a PEG compound which composed of DSPE and a KDR targeting peptide (K237). K237 can functionally disrupt the interaction between VEGF and the KDR receptor and cause potent biological effects that include the inhibition of angiogenesis and tumor growth. DSPE-PEG3400-K237 can be used for drug delivery .
DSPE-PEG5000-K237 is a PEG compound which composed of DSPE and a KDR targeting peptide (K237). K237 can functionally disrupt the interaction between VEGF and the KDR receptor and cause potent biological effects that include the inhibition of angiogenesis and tumor growth. DSPE-PEG5000-K237 can be used for drug delivery .
DSPE-PEG2000-K237 is a PEG compound which composed of DSPE and a KDR targeting peptide (K237). K237 can functionally disrupt the interaction between VEGF and the KDR receptor and cause potent biological effects that include the inhibition of angiogenesis and tumor growth. DSPE-PEG2000-K237 can be used for drug delivery .
DSPE-PEG1000-K237 is a PEG compound which composed of DSPE and a KDR targeting peptide (K237). K237 can functionally disrupt the interaction between VEGF and the KDR receptor and cause potent biological effects that include the inhibition of angiogenesis and tumor growth. DSPE-PEG1000-K237 can be used for drug delivery .
KLTWQELYQLKYKGI (QK) is a VEGF mimicking peptide, binds to the VEGFreceptors and competes with VEGF. KLTWQELYQLKYKGI is active in gastric ulcer healing in rodents when administered either orally or systemically. KLTWQELYQLKYKGI shows the ability to induce capillary formation and organization in vitro .
Gersizangitide (AXT107) is an anti-angiogenic peptide consisting of 20 amino acids, derived from collagen IV. Gersizangitide is an inhibitor of VEGF-A and VEGF-C and an activator of Tie2. Gersizangitide can block VEGFreceptor signaling, inhibit vascular leakage, neovascularization and inflammation. Gersizangitide can be used in the research of diseases related to ocular neovascularization and angiogenesis .
Boc-Phe-Leu-Phe-Leu-Phe (Boc-FLFLF) is a N-formyl peptide receptors (FPR) inhibitor. Boc-Phe-Leu-Phe-Leu-Phe abolishes the FMLP-induced release of peptide leukotrienes. Boc-Phe-Leu-Phe-Leu-Phe inhibits the sprouting of human umbilical vein endothelial cell (HUVEC) spheroids mediated by proliferative diabetic retinopathy (PDR) vitreous and vascular endothelial growth factor (VEGF) respectively in a three-dimensional fibrin gel. Boc-Phe-Leu-Phe-Leu-Phe inhibits the anti-inflammatory and antifibrotic effects of Ac2-26 (HY-P1098). Boc-Phe-Leu-Phe-Leu-Phe can be used for the study of immunology .
VGB4 is a VEGF-A and VEGF-B antagonist peptide that duplicates two binding domains of VEGF-B (loop 1 and loop3) and are linked together by the receptor-binding domain of VEGF-A (loop3). VGB4 has significant anti-angiogenic and anti-tumor activities and can regulate tumor growth and metastasis through multiple mechanisms. VGB4 could be used in anti-tumor research .
Vanucizumab is a first-in-class, bispecific IgG1-like monoclonal antibody that simultaneously blocks VEGF-A and angiopoietin-2 (Ang-2) from interacting with their receptors. Vanucizumab has antiangiogenic and anticancer effects .
Inlecitug is a chimeric monoclonal antibody targeting human KDR (kinase insert domain receptor). Inlecitug specifically binds to KDR, blocking the binding of vascular endothelial growth factor (VEGF) to KDR and inhibiting angiogenesis, thus exerting antitumor activity. Inlecitug is promising for research of cancers .
Lavendustin A (RG-14355) is a potent, selective and ATP-competitive inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, with an IC50 of 11 nM. Lavendustin A does not inhibit protein kinase A or C. Lavendustin A can suppress VEGF-induced angiogenesis .
Lavendustin A (Standard) is the analytical standard of Lavendustin A. This product is intended for research and analytical applications. Lavendustin A (RG-14355) is a potent, selective and ATP-competitive inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, with an IC50 of 11 nM. Lavendustin A does not inhibit protein kinase A or C. Lavendustin A can suppress VEGF-induced angiogenesis[1][2].
Azaspirene ((-)-Azaspirene) is an angiogenesis and Raf-1 activation inhibitor isolated from the fungus Neosartorya sp. Azaspirene inhibits vascular endothelial growth factor (VEGF)-induced human umbilical vein endothelial cell (HUVEC) migration and Raf-1 activation, but has no effect on the activation of kinase insert domain-containing receptor/fetal liver kinase 1 (VEGFreceptor 2) .
VEGFR-2 is a tyrosine-protein kinase of the cell surface receptors of VEGFA, VEGFC, and VEGFD that mediates activation of the MAPK1/ERK2, MAPK3/ERK1, and MAP kinase signaling pathways, as well as the AKT1 signaling pathway. VEGFR-2 can promote the proliferation, survival, migration and differentiation of endothelial cells. Overexpression of VEGFR-2 is associated with the development of tumors. VEGFR-2 Protein, Human (HEK293, His) is the recombinant human-derived VEGFR-2 protein, expressed by HEK293 , with C-His labeled tag.
VEGFR-2 protein is a tyrosine protein kinase receptor for VEGFA, VEGFC and VEGFD and is critical in angiogenesis, blood vessel development and embryonic hematopoiesis. It promotes endothelial cell function and actin cytoskeletal reorganization. VEGFR-2 Protein, Human (745a.a, HEK293, Fc) is the recombinant human-derived VEGFR-2 protein, expressed by HEK293 , with C-hFc labeled tag.
Neuropilin-1 protein is a cell surface receptor that plays multiple roles in cardiovascular development, angiogenesis, and neuronal circuit formation. It mediates chemical repulsion by recognizing ligands with CendR motifs, leading to internalization and vascular leakage. Neuropilin-1 Protein, Rat (HEK293, His) is the recombinant rat-derived Neuropilin-1 protein, expressed by HEK293 , with C-6*His labeled tag and K811R, P812-G828 delet.
VEGFR-2 protein is a tyrosine protein kinase receptor for VEGFA, VEGFC and VEGFD and is critical in angiogenesis, blood vessel development and embryonic hematopoiesis. It promotes endothelial cell function and actin cytoskeletal reorganization. VEGFR-2 Protein, Human (HEK293, His-Avi) is the recombinant human-derived VEGFR-2 protein, expressed by HEK293 , with C-Avi, C-6*His labeled tag.
Carebastine-d5 is the deuterium labeled Carebastine. Carebastine is the active metabolite of Ebastine. Carebastine is a histamine H1 receptor antagonist. Carebastine inhibits VEGF-induced HUVEC and HPAEC proliferation, migration and angiogenesis in a dose-dependent manner . Carebastine suppresses the expression of macrophage migration inhibitory factor .
Carebastine-d5 Methyl Ester is the deuterium labeled Carebastine. Carebastine is the active metabolite of Ebastine. Carebastine is a histamine H1 receptor antagonist. Carebastine inhibits VEGF-induced HUVEC and HPAEC proliferation, migration and angiogenesis in a dose-dependent manner . Carebastine suppresses the expression of macrophage migration inhibitory factor .
Human KDR mRNA encodes the human kinase insert domain receptor (KDR) protein, a receptor of vascular endothelial growth factor (VEGF). KDR functions as the main mediator of VEGF-induced endothelial proliferation, survival, migration, tubular morphogenesis and sprouting.
DSPE-PEG5000-K237 is a PEG compound which composed of DSPE and a KDR targeting peptide (K237). K237 can functionally disrupt the interaction between VEGF and the KDR receptor and cause potent biological effects that include the inhibition of angiogenesis and tumor growth. DSPE-PEG5000-K237 can be used for drug delivery .
DSPE-PEG2000-K237 is a PEG compound which composed of DSPE and a KDR targeting peptide (K237). K237 can functionally disrupt the interaction between VEGF and the KDR receptor and cause potent biological effects that include the inhibition of angiogenesis and tumor growth. DSPE-PEG2000-K237 can be used for drug delivery .
DSPE-PEG1000-K237 is a PEG compound which composed of DSPE and a KDR targeting peptide (K237). K237 can functionally disrupt the interaction between VEGF and the KDR receptor and cause potent biological effects that include the inhibition of angiogenesis and tumor growth. DSPE-PEG1000-K237 can be used for drug delivery .
Inquiry Online
Your information is safe with us. * Required Fields.
